story of the week
Efficacy and Safety of 24-Week All-Oral Regimens for Rifampin-Resistant Tuberculosis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis
N. Engl. J. Med 2022 Dec 22;387(25)2331-2343, BT Nyang'wa, C Berry, E Kazounis, I Motta, N Parpieva, Z Tigay, V Solodovnikova, I Liverko, R Moodliar, M Dodd, N Ngubane, M Rassool, TD McHugh, M Spigelman, DAJ Moore, K Ritmeijer, P du Cros, K FieldingFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.